Pulsed dose oxygen delivery system

Dr Garrod and colleagues have described a pulsed flow oxygen delivery system for use during exercise by patients with chronic obstructive pulmonary disease (COPD).1 They found the device to be four times as economical as nasal cannulae for the same increase in walking distance in patients with COPD compared with the other devices which were tested.1 2

The Haldane type mask fell out of use because, with a limited demand and low price, the manufacturer had little incentive to maintain a stock. Now, with greater awareness of the likely benefit, there might be a case for trying again.

J E COTES
Department of Physiological Sciences, Medical School, Newcastle upon Tyne NE2 4HH, UK


Simian virus 40 and human pleural mesothelioma

Mulatero et al report failure to detect Simian virus 40 (SV40) DNA in 12 British mesotheliomas. The poor sensitivity of their negative results indicates that the previous positive findings are probably a consequence of PCR contamination. Since Mulatero et al submitted their paper, several laboratories have further confirmed the association of SV40 with human mesothelioma and other types of human tumors.1 2 Furthermore, the International Mesothelioma Interest Group has published results of their multinational investigation confirming consistent association of SV40 DNA with mesotheliomas.3 Additional recent studies (reviewed by Butel and Lednický)4 have shown SV40 DNA to exist in an integrated form in human tumours and to be associated with expression of SV40 large T antigen as demonstrated by RNA in situ hybridisation, Western blotting, and immunostaining. These results therefore contradict the PCR contamination theory. The negative findings of Mulatero et al may be explained by technical or demographic differences.5

The authors state that the sensitivity of their assay is one SV40 genome per cell based on a PCR methodology capable of detecting HPV. This level of sensitivity is below the threshold for detecting SV40 in human mesothelioma, partly because of the usual low proportion of tumour cells included in mesothelioma biopsy specimens and partly because of the low copy number (<50 copies per cell) of SV40 DNA integrated to be associated with this tumour type.6 In this context, the adequacy of method sensitivity claimed by the authors based on its comparability with sensitivity of an assay capable of detecting HPV in cervical cancer is potentially misleading. Cervical cancer is not only a more cellular tumour but is known to be associated with several to hundreds of viral genomic copies per tumour cell. We therefore suggest that the specimens of Mulatero et al should be re-tested using a more sensitive methodology to establish whether their negative findings are related to technical or demographic differences.

BHARAT JASANI
Molecular Pathology & Immunocytochemistry Unit, University of Wales College of Medicine, Department of Pathology, Health Park, Cardiff CF14 4XX, UK


AUTHORS’ REPLY

Dr Jasani misquotes us when he says we suggested the presence of SV40 may be greater in the USA than in Europe, possibly as a consequence of technical or demographic differences. It appears from the collective results of various studies that the prevalence of SV40 in mesothelioma may be greater in the USA than in Europe, possibly as a consequence of contamination of samples as one of several possible explanations for differing results. Dr Jasani suggests that our failure to identify SV40 may be due to inadequate sensitivity and he states that the sensitivity of our assay, which we reported at one copy of SV40 per cell, is below the threshold for detecting SV40 in human mesotheliomas. All the studies referred to by our co-author,2 did not report sensitivity of more than one copy per cell.

The multi-institutional study to which Dr Jasani refers examined only 12 cases of mesothelioma from one hospital in New York, but the samples were analysed in four laboratories including one in Finland which had previously reported negative results for SV40 in local mesotheliomas. All the authors rejected the possibility that he may be correct, but he does not identify any evidence to support his assertion. The studies which have identified SV40 in mesotheliomas from Finland refer, including one of which he was a co-author,2 did not report sensitivity of more than one copy per cell.
more widespread use of contaminated polio vaccine in the USA. However, epidemiological evidence indicates that the incidence of mesothelioma in the USA has peaked, whereas a continuing increase in incidence over the next 20 years is expected in Europe.1 These observations, together with evidence that so far there is no increase in the incidence of mesothelioma in individuals who received SV40 contaminated polio vaccine, do not suggest that SV40 is important in the causation of human mesothelioma.

R M RUDD C MULATERO on behalf of the authors Medical Oncology Department, St Bartholomew’s Hospital, London E1A 7BE, UK


Acronyms

I write to protest against the use of unexplained acronyms in your editorial entitled “EUROSCOP, ISOLDE and the Copenhagen City Lung Study”.1 Acronyms are useful and often necessary because they simplify and accelerate modern communication.2 But when first mentioned in any biomedical journals, acronyms must be explained fully.3 Furthermore, abbreviations are prohibited in a title.4 Specialists often take for granted that certain “trade terms” are so evident that they do not bother to define them. I thought that cystic fibrosis related diabetes (CFRD) was one such acronym, so I asked my patient what it meant. She thought that it was a terrible disease.5

Further reading


Methacholine challenge and sputum induction

Spanevello and colleagues claim that a methacholine inhalation challenge carried out one hour before sputum induction in patients with stable asthma does not significantly alter the cellular, eosinophilic cationic protein (ECP), or albumin constituents of sputum.7 These results, if correct, are important both for clinical practice and clinical trials where information regarding airway hyperresponsiveness and inflammation is needed. Being able to perform a methacholine challenge and sputum induction on the same day would be of immense practical value.

Sixteen subjects with asthma were studied on two days within a week. Sputum induction was performed alone on one day and one hour after a methacholine challenge on the other. Cell counts and the biochemical constituents of the two sputum samples were compared using the Wilcoxon signed rank test and a value of p<0.05 was considered statistically significant.

The small sample size, variability in the data, and p values near significance for neutrophils (p=0.06) and macrophages (p=0.08) led us to determine the power of the study. The results of a power analysis for paired continuous data showed that the study only had a 36%, 29%, 10%, 6.6%, and 19.5% chance of detecting a difference for macrophage, neutrophil, eosinophil, lymphocyte and epithelial cell counts, respectively, and 6.0% and 15.3% for ECP and albumin.

Hence, while methacholine may not influence sputum cell counts, this study is too underpowered to reach this conclusion.

N RENÉE LABRIS F E HARGREAVE Asthma Research Group, St Joseph’s Hospital and McMaster University, 50 Charlton Avenue East, Hamilton, Ontario, Canada L8N 4A6

rhDNase in cystic fibrosis

Cystic fibrosis is a disease that is relatively rare but expensive for patients, families, and carers. The introduction of rhDNase has been associated with controversy as to its benefits and costs. Milla describes the experience in a centre that prescribed this drug to patients, 60% of whom had an FEV1 of more than 80% predicted at the time of prescription. Overall, the group had an accelerated decline in lung function following its introduction. This study illustrates the importance of patient selection and follow up in the prescription of rhDNase.

Paediatricians and chest physicians from the South & West Region of the UK have audited their use of DNase as part of their contribution to the South & West Cystic Fibrosis database. In 1995 78 (12%) of the 664 patients receiving care within the region had been prescribed DNase. This had risen to 143 (22%) in 1996. We subsequently defined criteria for its use: patients over five years of age, FEV1 <70% predicted, and more than one course of intravenous antibiotics during the previous year. In 1995 12 (17%) of patients receiving DNase did not appear to meet these clinical criteria. A further 36 patients who were eligible under these criteria were not receiving the drug.

Innes' rightly emphasises the responsibility of carers to target this treatment effectively — it is also important that treatment is seen to be equitable and not dependent on postcode. Our experience illustrates that a regional cystic fibrosis database can be seen as a clinically relevant and cost effective device for targeting appropriate treatment. The annual cost of DNase for two patients would be sufficient to fund a regional audit to monitor and influence this and other expensive treatments in patients with cystic fibrosis.

J C TYRRELL
P A LEWIS
School of Postgraduate Medicine,
University of Bath, Bath,
Somerset BA2 7AY, UK

C D SHELTON
Department of Respiratory Medicine,
Royal Devon & Exeter Hospital,
Exeter, Devon EX2 5DW, UK

G CONNETT
Paediatric Medical Unit,
Southampton General Hospital,
Southampton SO16 6YD, UK
(on behalf of the South & West CF Group)

